Day: February 26, 2025

TORONTO, Feb. 26, 2025 (GLOBE NEWSWIRE) — Sprott Inc. (NYSE/TSX: SII) (“Sprott” or the “Company”) today announced its financial results for the year ended December 31, 2024. Management commentary “Sprott’s Assets Under Management (“AUM”) ended the year at $31.5 billion, down 6% from $33.4 billion as at September 30, 2024, but up 10% from $28.7 billion as at December 31, 2023. 2024 was our seventh consecutive year of double-digit AUM growth and, subsequent to year-end, as at February 21, 2025, AUM had further increased to $33.5 billion, up $2 billion, or 6% from December 31, 2024,” said Whitney George, Chief Executive Officer of Sprott. “During the year we benefited from strong precious metals prices as well as $698 million in net sales, primarily in our physical trusts and uranium and critical materials ETFs.” “The...

BANNOCKBURN, Ill., Feb. 26, 2025 (GLOBE NEWSWIRE) — Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial HighlightsNet revenue of $1,346.4 million, up 19.7% compared to $1,124.4 million in the fourth quarter of 2023 Gross profit of $268.4 million, or 19.9% of net revenue, up 8.6% compared to $247.1 million, or 22.0% of net revenue, in the fourth quarter of 2023 Net income of $60.1 million, compared to net income of $57.2 million, in the fourth quarter of 2023 and diluted earnings per share of $0.35, up 9.4% compared to diluted earnings per share of $0.32 in the fourth quarter of 2023 Adjusted...

Fourth-quarter and full-year 2024 Rezdiffra net sales of $103.3 million and $180.1 million, respectively As of year-end 2024, more than 11,800 patients on Rezdiffra Reports cash, cash equivalents, restricted cash and marketable securities of $931.3 million at December 31, 2024 Announces new two-year data for the active-treatment open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial Company to host conference call today, February 26, 2025, at 8 a.m. ESTCONSHOHOCKEN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports fourth-quarter and year-end 2024 financial results and reviews business highlights. Bill Sibold, Chief Executive...

Fourth Quarter Highlights(All metrics compared to the fourth quarter of fiscal 2024)Contract revenues of $1.085 billion, up 13.9% Adjusted EBITDA of $116.4 million, or 10.7% of contract revenues, up 89 basis points Net income of $32.7 million, or $1.11 per common share diluted Adjusted Net Income of $34.5 million; Adjusted EPS of $1.17 per common share diluted, up 48.1% Total backlog of $7.760 billion as of January 25, 2025 Repurchased 200,000 shares for $35.9 millionAnnual Highlights(All metrics compared to fiscal 2024)Contract revenues of $4.702 billion, up 12.6% Adjusted EBITDA of $576.3 million, or 12.3% of contract revenues Net income of $233.4 million, or $7.92 per common share diluted Adjusted Net Income of $248.7 million; Adjusted EPS of $8.44 per common share diluted, up 24.5% Operating Cash Flow of $349.1 million, up 34.8% Repurchased...

BROOKFIELD, Conn., Feb. 26, 2025 (GLOBE NEWSWIRE) — Photronics, Inc. (NASDAQ:PLAB), a worldwide leader in photomask technologies and solutions, today reported financial results for its first quarter of fiscal year 2025 ended February 2, 2025. “We achieved top-line results in line with our expectations and reflective of seasonal demand patterns,” said Frank Lee, chief executive officer. “Within Integrated Circuits (IC) and Flat Panel Display (FPD) end markets, we observed favorable demand for high-end products while the most mature mainstream masks were impacted by general market softness. In IC, photomasks supporting node migration and memory were particularly strong. In FPD, we continue to strategically leverage our IC technical expertise to drive our market leading position and market share gains. We remain cautious about 2025,...

— Fourth quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $41.8 million — — On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the second quarter of 2025 —  — Completed enrollment in the Phase 2 trial of oral MC4R agonist bivamelagon in acquired hypothalamic obesity — — FDA approved expanded label for IMCIVREE to include children as young as 2 years old — — Raised approximately $75 million in gross proceeds under ATM equity offering program; Cash runway extended into 2027 — — Management to host conference call today at 8:00 a.m. ET — BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company...

Fourth Quarter Net Sales Increased 20% with Full Year Increasing 5% to $516 million benefiting from Vita Coco Coconut Water growth of 10%  Full Year Net Income Increased $9 million to $56 million and Non-GAAP Adjusted EBITDA1 Increased $16 million to $84 million For Fiscal Year 2025, Expect Net Sales between $555 and $570 million and Adjusted EBITDA2 between $86 and $92 million NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) — The Vita Coco Company, Inc. (NASDAQ:COCO) (“Vita Coco” or “the Company”), a leading high-growth platform of better-for-you beverage brands, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter and Full Year 2024 Highlights Compared to Prior YearNet sales increased 20% in the fourth quarter to $127 million resulting in full year net sales of $516 million. Vita...

Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024 Free cash flow was $141.4 million and $493.1 million for the fourth quarter and full year 2024 GAAP fully diluted loss per share of $(0.17) and earnings per share of $4.36 for the fourth quarter and full year 2024 Adjusted fully diluted earnings per share of $1.59 and $6.76 for the fourth quarter and full year 2024 PYLARIFY exceeds $1 billion in net sales and becomes first ever blockbuster radiodiagnostic Company announces a series of strategic asset and in-licensing deals that is expected to diversify its portfolio with early- to late-stage assets that position the company for continued growth in high potential markets Company provides full year 2025 revenue and adjusted diluted earnings per share guidanceBEDFORD, Mass., Feb. 26, 2025 ...